Drugs / Havrix Inj
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT03654677 Comparator | Sep 2017 → Oct 2018 | hepatitis A virus infection | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT03654664 Comparator | Jun 2017 → Jun 2019 | hepatitis A virus infection | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Havrix Inj. | “using a previously approved inactivated hepatitis A vaccine (Havrix Inj., manufactured by GSK) as the control vaccine” NCT03654677 ↗ |
| Modality | Vaccine | “a previously approved inactivated hepatitis A vaccine (Havrix Inj., manufactured by GSK)” NCT03654664 ↗ |